Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 11/20 | 0.62 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8495527 | 1.00 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| SCHEMBL42034 | 0.97 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| Hydrochloric Acid SCHEMBL737731 | 0.97 | HRH3 (0.57) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| SCHEMBL10975327 | 0.97 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| SCHEMBL6442113 | 0.97 | HRH3 (0.65) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| SCHEMBL11550922 | 0.95 | HRH3 (0.62) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| SCHEMBL73078 | 0.95 | — | — | |
| Hydrochloric Acid SCHEMBL7101066 | 0.92 | HRH3 (0.67) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| Hydrochloric Acid SCHEMBL16698377 | 0.92 | HRH3 (0.59) | HRH3CYP1A2MAPK1SMN1; SMN2ACHE | |
| Hydrochloric Acid SCHEMBL10473504 | 0.90 | HRH3 (0.71) | HRH3CYP1A2MAPK1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 604 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110627744-A | Preparation method of difenidol hydrochloride intermediate | 株洲千金药业股份有限公司 | 2019-12-31 | — | — | CN | claimed |
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | ABIVAX (FR) | 2025-03-27 | — | — | US | disclosed |
| WO-2025042896-A1 | DNA TOPOISOMERASE IIβ INHIBITORS | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-02-27 | — | — | WO | disclosed |
| CN-119431355-A | Phenyl thiazole derivative, composition and application thereof | 徐州医科大学 | 2025-02-14 | — | — | CN | disclosed |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | ABIVAX (FR) | 2025-01-21 | — | — | US | disclosed |
| EP-3998070-B1 | MIR-124 AS A BIOMARKER FOR THE TREATMENT OF INFLAMMATORY DISEASES | ABIVAX (FR) | 2024-12-18 | — | — | EP | disclosed |
| US-12139470-B2 | Trioxolane agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-12 | — | — | US | disclosed |
| CN-118451062-A | Preparation and use of quinazolinediones | 科学与工业研究会(按照印度社会团体注册法案(1860年第21号法案)设立的注册机构) | 2024-08-06 | — | — | CN | disclosed |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | University of Florida Research Fooundation, Incorporated (US) | 2024-07-25 | — | — | US | disclosed |
| US-4094870-A | 2-Substituted thio-1,4-benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-06-13 | — | — | US | disclosed |
| US-4059702-A | ANTIVIRAL | RICHARDSON-MERRELL INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-4045432-A | Antidepressant 1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]-cyclohepten-6-substituted oximes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-08-30 | — | — | US | disclosed |
| US-4041165-A | TREATING DELAYED HYPERSENSITIVITY | RICHARDSON-MERRELL INC. (US) | 1977-08-09 | — | — | US | disclosed |
| US-4015003-A | Antidepressant 1,1a,6,10b-tetrahydrodibenzo[a,e]-cyclopropa-[c]-cyclohepten-6-substituted oximes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-4014936-A | Antidepressant 1,1a,6,10b-tetrahydrodibenzo[a,e]-cyclopropa-[c]-cyclohepten-6-substituted oximes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-03-29 | — | — | US | disclosed |
| US-4008331-A | Antidepressant 1,1a,6,10b-tetrahydrodibenzo-[a,e]-cyclopropa-[c]-cyclohepten-6-substituted oximes | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-02-15 | — | — | US | disclosed |
| US-3994890-A | TRANQUILIZERS, ANTIDEPRESSANTS, ANTIINFLAMMATORY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) | 1976-11-30 | — | — | US | disclosed |
| US-3960956-A | Antidepressant 1,1a,6,10b-tetrahydrodibenzo(a,e)-cyclo-propa(c) cyclohepten-6-substituted oximes | E. I. DU PONT DE NEMOURS & COMPANY (US) | 1976-06-01 | — | — | US | disclosed |
| US-3937833-A | DELAYED HYPERSENSITIVITY | RICHARDSON-MERRELL INC. (US) | 1976-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12139470-B2 | Trioxolane agents | ABCB4, SLC10A1, SLC10A2 | HRH3 2136/4885ACHE 1722/4885CYP1A2 2605/4885 |
| US-12202804-B2 | In vitro or ex vivo methods for screening a quinoline derivative | CD14, MYADM, SYNCRIP | HRH3 993/4885ACHE 2477/4885CYP1A2 3445/4885 |
| US-20240246943-A1 | MULTIFACETED APPROACH TO NOVEL INTERLEUKIN-6 INHIBITORS | IL6, IL6ST, IL36G | HRH3 3168/4885ACHE 2317/4885CYP1A2 3681/4885 |
| US-20250100971-A1 | IN VITRO OR EX VIVO METHODS FOR SCREENING A QUINOLINE DERIVATIVE | SSB, SYVN1, TLR7 | HRH3 500/4885ACHE 1057/4885CYP1A2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.